Eva Guinan, MD, is a pediatric hematologist/oncologist and an international expert in bone marrow failure and stem cell transplantation. She graduated from Harvard College and Harvard Medical School. She has been the senior investigator for clinical trials in human stem cell transplantation, as well as innovative proof of concept studies arising from her laboratory work where she developed the use of novel biological approaches to the problem of mismatched transplantation. She and her collaborators have discovered a novel radiation mitigation strategy also for use after unintended radiation exposures such as Fukishima, or to moderate therapeutic radiation toxicity. This agent appears to have unexpected roles in hematopoiesis that can be used to address other diseases states. To pursue that research and put her background in clinical/translational research to full use, she joined the Department of Radiation Oncology at the DFCI as its first director of Translational Research. She is also the director of the Harvard Catalyst Translational Innovation program which works to initiate novel approaches to important clinical questions and, in her LISH role,  implement empiric experiments designed to explore whether distributed innovation techniques, alternative evaluation approaches, and novel concepts in team formation can be effective within the academic biomedical community.